Review Article

Abdominal obesity and metabolic syndrome

Abstract

Metabolic syndrome is associated with abdominal obesity, blood lipid disorders, inflammation, insulin resistance or full-blown diabetes, and increased risk of developing cardiovascular disease. Proposed criteria for identifying patients with metabolic syndrome have contributed greatly to preventive medicine, but the value of metabolic syndrome as a scientific concept remains controversial. The presence of metabolic syndrome alone cannot predict global cardiovascular disease risk. But abdominal obesity — the most prevalent manifestation of metabolic syndrome — is a marker of 'dysfunctional adipose tissue', and is of central importance in clinical diagnosis. Better risk assessment algorithms are needed to quantify diabetes and cardiovascular disease risk on a global scale.

  • Subscribe to Nature for full access:

    $199

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J. Am. Coll. Cardiol. 47, 1093–1100 (2006).

  2. 2.

    Does a diagnosis of metabolic syndrome have value in clinical practice? Am. J. Clin. Nutr. 83, 1248–1251 (2006).

  3. 3.

    Drug therapy of the metabolic syndrome: minimizing the emerging crisis of polypharmacy. Nature Rev. Drug Discov. 5, 295–309 (2006).

  4. 4.

    & Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med. 56, 45–62 (2005).

  5. 5.

    The metabolic syndrome: should current criteria influence clinical practice? Curr. Opin. Lipidol. 17, 404–411 (2006).

  6. 6.

    , & The metabolic syndrome. Lancet 365, 1415–1428 (2005).

  7. 7.

    The metabolic syndrome: is this diagnosis necessary? Am. J. Clin. Nutr. 83, 1237–1247 (2006).

  8. 8.

    Is insulin resistance the cause of the metabolic syndrome? Ann. Med. 38, 43–51 (2006).

  9. 9.

    The myth of the metabolic syndrome. Diabetologia 48, 1679–1683 (2005).

  10. 10.

    , , & The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28, 2289–2304 (2005).

  11. 11.

    The metabolic syndrome: requiescat in pace. Clin. Chem. 51, 931–938 (2005).

  12. 12.

    & Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998).

  13. 13.

    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285, 2486–2497 (2001).

  14. 14.

    , & The metabolic syndrome — a new worldwide definition. Lancet 366, 1059–1062 (2005).

  15. 15.

    , & Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am. J. Med. 119, 812–819 (2006).

  16. 16.

    et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. J. Am. Med. Assoc. 289, 76–79 (2003).

  17. 17.

    , & Global and societal implications of the diabetes epidemic. Nature 414, 782–787 (2001).

  18. 18.

    & Redefining type 2 diabetes:'diabesity' or 'obesity dependent diabetes mellitus'? Obesity Rev. 1, 57–59 (2000).

  19. 19.

    Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Diabetes Metab. 22, 122–131 (1996).

  20. 20.

    Paul Zimmet: fighting the 'diabesity' pandemic. Lancet 368, 1643 (2006).

  21. 21.

    et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler. Thromb. Vasc. Biol. 20, 1932–1938 (2000).

  22. 22.

    , , , & Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes 46, 456–462 (1997).

  23. 23.

    WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157–163 (2004).

  24. 24.

    et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int. J. Obes. (Lond.) 30, 1163–1165 (2006).

  25. 25.

    , , & Abdominal fat distribution and metabolic risk factors: effects of race. Metabolism 45, 1119–1124 (1996).

  26. 26.

    , & Intrabdominal adipose tissue and anthropometric surrogates in African American women with upper- and lower-body obesity. Am. J. Clin. Nutr. 66, 1345–1351 (1997).

  27. 27.

    , , , & Relationship between obesity, insulin resistance, and coronary heart disease risk. J. Am. Coll. Cardiol. 40, 937–943 (2002).

  28. 28.

    et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10, 497–511 (1990).

  29. 29.

    Is visceral obesity the cause of the metabolic syndrome? Ann. Med. 38, 52–63 (2006).

  30. 30.

    Metabolic implications of body fat distribution. Diabetes Care 14, 1132–1143 (1991).

  31. 31.

    & Regional adiposity and morbidity. Physiol. Rev. 74, 761–811 (1994).

  32. 32.

    & Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 28, 2322–2325 (2005).

  33. 33.

    , , & Extreme insulin resistance of the central adipose depot in vivo. Diabetes 51, 755–761 (2002).

  34. 34.

    et al. Regional variation in adipose tissue metabolism of severely obese premenopausal women. J. Lipid. Res. 36, 672–684 (1995).

  35. 35.

    et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 14 (Suppl. 1), 16S–19S (2006).

  36. 36.

    Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity (Silver Spring) 14 (Suppl. 1), 20S–24S (2006).

  37. 37.

    et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808 (2003).

  38. 38.

    , , & C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19, 972–978 (1999).

  39. 39.

    , & C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol. 47, C19–C31 (2006).

  40. 40.

    et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 21, 961–967 (2001).

  41. 41.

    et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem. Biophys. Res. Commun. 221, 286–289 (1996).

  42. 42.

    , , , & A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270, 26746–26749 (1995).

  43. 43.

    et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J. Clin. Endocrinol. Metab. 90, 1434–1439 (2005).

  44. 44.

    & Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96, 939–949 (2005).

  45. 45.

    Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nature Clin. Pract. Cardiovasc. Med. 3, 35–42 (2006).

  46. 46.

    et al. Contribution of interleukin-6 and tumor necrosis factor-alpha to the elevated C-reactive protein levels found in abdominally obese men. Obes. Res. 9, 66S (2001).

  47. 47.

    Molecular mechanisms of insulin resistance and the role of the adipocyte. Int. J. Obes. Relat. Metab. Disord. 24 (Suppl. 4), S23–S27 (2000).

  48. 48.

    Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr. Opin. Lipidol. 13, 51–59 (2002).

  49. 49.

    Energy partitioning in gluteal-femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk? Arterioscler. Thromb. Vasc. Biol. 24, 795–797 (2004).

  50. 50.

    , , & Metabolic syndrome: definition, pathophysiology, and mechanisms. Am. Heart J. 149, 33–45 (2005).

  51. 51.

    et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105, 271–278 (2000).

  52. 52.

    , , , & Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J. Biol. Chem. 275, 8456–8460 (2000).

  53. 53.

    & Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinol. Metab. Clin. North Am. 33, 305–331 (2004).

  54. 54.

    Failure of adipocyte differentiation causes type II diabetes mellitus? Nature Genet. 26, 13 (2000).

  55. 55.

    et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87, 2784–2791 (2002).

  56. 56.

    , , , & Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112, 3066–3072 (2005).

  57. 57.

    et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 156, 1070–1077 (2002).

  58. 58.

    , & Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann. Intern. Med. 136, 575–581 (2002).

  59. 59.

    , & Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 25, 1790–1794 (2002).

  60. 60.

    et al. A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring. Am. Heart J. 151, 754.e7–754.e17 (2006).

  61. 61.

    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).

  62. 62.

    & Diabetic macrovascular disease: the glucose paradox? Circulation 106, 2760–2763 (2002).

  63. 63.

    Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48, 937–942 (1999).

  64. 64.

    et al. Definition of metabolic syndrome. Report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433–438 (2004).

  65. 65.

    et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes 51, 3069–3076 (2002).

  66. 66.

    et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837–1847 (1998).

  67. 67.

    , , & Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch. Intern. Med. 165, 2644–2650 (2005).

  68. 68.

    , , , & Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 27, 2676–2681 (2004).

  69. 69.

    , & Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105, 310–315 (2002).

  70. 70.

    et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am. J. Cardiol. 93, 136–141 (2004).

  71. 71.

    et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. J. Am. Med. Assoc. 279, 1955–1961 (1998).

  72. 72.

    Insulin resistance in human partial lipodystrophy. Curr. Atheroscler. Rep. 2, 397–404 (2000).

  73. 73.

    & Cigarette smoking and increased central adiposity. Ann. Intern. Med. 111, 783–787 (1989).

  74. 74.

    , & Studies in the distribution of body fat. III. Effects of cigarette smoking. J. Am. Med. Assoc. 261, 1169–1173 (1989).

  75. 75.

    & Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease? J. Am. Coll. Cardiol. 41, 1044–1047 (2003).

  76. 76.

    et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41, 826–834 (1992).

  77. 77.

    , & Treatment of obesity: need to focus on high risk abdominally obese patients. Brit. Med. J. 322, 716–720 (2001).

  78. 78.

    et al. Obesity and central fat pattern among Greenland Inuit and a general population of Denmark (Inter99): relationship to metabolic risk factors. Int. J. Obes. Relat. Metab. Disord. 27, 1507–1515 (2003).

  79. 79.

    et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann. Intern. Med. 133, 92–103 (2000).

  80. 80.

    et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med. 142, 611–619 (2005).

  81. 81.

    et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Med. Sci. Sports Exerc. 35, 1703–1709 (2003).

  82. 82.

    , , , & Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. Int. J. Obes. Relat. Metab. Disord. 25, 1136–1143 (2001).

  83. 83.

    & Response of blood lipids to exercise training alone or combined with dietary intervention. Med. Sci. Sports Exerc. 33, S502–S515 (2001).

  84. 84.

    et al. Waist girth does not predict metabolic complications in severely obese men. Diabetes Care 29, 1417–1419 (2006).

  85. 85.

    et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men? Circulation 102, 179–184 (2000).

  86. 86.

    Cardiovascular risk, the metabolic syndrome and the hypertriglyceridaemic waist. Curr. Opin. Lipidol. 15, 495–497 (2004).

  87. 87.

    & Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. Am. J. Clin. Nutr. 78, 928–934 (2003).

  88. 88.

    , & Waist circumference as a measure for indicating need for weight management. Br. Med. J. 311, 158–161 (1995).

  89. 89.

    et al. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am. J. Clin. Nutr. 76, 743–749 (2002).

  90. 90.

    New ADA initiative moves beyond 'metabolic syndrome'. 'Cardiometabolic risk' proposed as umbrella term for diabetes risk factors. DOC News 3, 1–3 (2006).

  91. 91.

    , , & Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 113, 2943–2946 (2006).

  92. 92.

    From CVD risk to cardiometabolic risk. Presented at the Symposium of the International Chair on Cardiometabolic Risk. XIV International Symposium on Atherosclerosis (Rome, 18–22 June 2006).

  93. 93.

    Visceral adiposity. Presented at the 66th Scientific Sessions, American Diabetes Association (Washington, DC, 9–13 June 2006).

  94. 94.

    et al. The response to long-term overfeeding in identical twins. N. Engl. J. Med. 322, 1477–1482 (1990).

Download references

Acknowledgements

The work of the authors has been supported by research grants from the Canadian Institutes of Health Research, the Canadian Diabetes Association, the Heart and Stroke Foundation and by the Foundation of the Québec Heart Institute. J.-P.D. is Scientific Director of the International Chair on Cardiometabolic Risk, which is supported by an unrestricted grant from Sanofi Aventis awarded to Université Laval.

Author information

Affiliations

  1. Québec Heart Institute, Hôpital Laval Research Centre, 2725 chemin Sainte-Foy, Pavilion Marguerite-D'Youville, 4th Floor, Quebec City, QC G1V 4G5, Canada.

    • Jean-Pierre Després
    •  & Isabelle Lemieux
  2. Division of Kinesiology, Department of Social and Preventive Medicine, Université Laval, Quebec City, QC G1K 7P4, Canada

    • Jean-Pierre Després

Authors

  1. Search for Jean-Pierre Després in:

  2. Search for Isabelle Lemieux in:

Competing interests

Jean-Pierre Després has received honoraria payments from the following pharmaceutical companies as a consultant or lecturer: Abbott Laboratories, AstraZeneca, Fournier Pharma/Solvay Pharma, GlaxoSmithKline, MSD, Pfizer Canada/Pharmacia, Sanofi-Aventis and Novartis.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.